no idea, page-4

Look we all know that the margins with generics are paper-thin. Let's not sugar-coat it now. They have gone off patent and rightly they should be sold cheaply for the benefit of patients that can't afford the next-generation treatment options.

I really can't understand why ACL is trading at these inflated levels. I will be very surprised if it doesn't correct sharply to the downside over the next six months. Strong sell.